anticancer drug that acts via inhibiting protein kinase C (PKC) and cyclin-dependent kinase 2 (CDK2). In pre-clinical studies, the compound exhibited potent anti-tumor effects both in vitro and in vivo. During clinical evaluation, the plasma concentrations of UCN-01 were much higher than predicted from non-clinical studies in experimental animals. The unexpectedly high plasma concentrations of ...